High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease

Current Opinion in Cardiology

Volumn 17, Issue 4, 2002, Pages 325-331

  Rosenson, Robert S ^a   Koenig, Wolfgang ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ACTIVITY; DISEASE MARKER; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; UNSTABLE ANGINA PECTORIS; ARTERIOSCLEROSIS; BLOOD; CLASSIFICATION; CORONARY ARTERY DISEASE; HEART INFARCTION; METABOLISM;

ANGINA PECTORIS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; HUMAN; INFLAMMATION; MYOCARDIAL INFARCTION; RISK FACTORS; HUMANS;

EID: 0036023622     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200207000-00001     Document Type: Review

References (71)

1. Emerging risk factors: Acute-phase reactants: Supplement on risk factors for coronary heart disease
2. Inflammation markers and coronary heart disease
3. Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analyses of prospective studies of coronary heart disease
4. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease
5. Variability in fibrinogen measurements: An obstacle to cardiovascular risk stratification
6. Oxidative stress as a regulator of gene expression in the vasculature
7. Atherosclerosis: An inflammatory disease
8. NF-κB: Pivotal mediator or innocent bystander in atherogenesis?
9. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
10. Direct proinflammatory effect of C-reactive protein on human endothelial cells
11. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
12. C-reactive protein mediated by low density lipoprotein uptake by macrophages: Implications for atherosclerosis
13. Complement activation by C-reactive protein complexes
14. The major receptor for C-reactive protein on leukocytes is FCγ receptor II
15. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
16. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
17. Elevated C-reactive protein levels with impaired endothelial vasoreactivity in patients with coronary artery disease
18. Acute systemic inflammation impairs endothelium-dependent dilatation in humans
19. Vasoreactivity of the culprit lesion in unstable angina
20. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina
21. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion
22. Production of C-reactive protein and risk of coronary events in stable and unstable angina
23. Elevation of C-reactive protein in "active" coronary artery disease
24. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
25. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
26. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
27. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
28. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
29. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy
30. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
31. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
32. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
33. Elevated levels of inteleukin-6 in unstable angina
34. Myocardial injury: The acute phase response and lipoprotein metabolism
35. Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: A pilot study
36. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction
37. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions
38. Induction of interleukin-6 synthesis in the myocardium: Potential role in postreperfusion inflammatory injury
39. Induction of cytokine expression in leukocytes in acute myocardial infarction
40. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction
41. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction
42. Serum C-reactive protein concentration in acute myocardial infarction and its relation to mortality during 4 months of follow-up in patients under thrombolytic treatment
43. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction
44. Production of C-reactive protein and risk of coronary events in stable and unstable angina
45. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events
46. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention
47. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
48. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
49. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
50. Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following on year of validated smoking cessation
51. Elevated C-reactive protein levels in overweight and obese adults
52. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
53. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
54. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
55. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study
56. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
57. The relation of markers of inflammation to the development of glucose disorders in the elderly: The cardiovascular health study
58. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
59. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
60. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay
61. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein
62. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis: CAPTURE Investigators: Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial
63. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
64. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
65. Long-term effects of pravastatin on plasma concentration of C-reactive protein
66. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
67. Effect of statins on C-reactive protein in patients with coronary artery disease
68. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
69. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
70. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
71. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators